The "BIVI stock forecast 2025" is showing mixed signals, with analysts projecting a potential trading range between $5.50 and $8.20 per share, contingent on R&D milestones. Recent quarterly reports indicate increased cash flow for clinical trials, which could be a bullish catalyst if results align with expectations. Traders should watch for institutional accumulation in Q3 So, the natural question for BioVie ( NASDAQ:BIVI ) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Volatility bands on "BIVI stock forecast 2025" suggest traders should prepare for sharp price movements post clinical-trial updates in Q1 and Q3
